Drug Profile
Research programme: topical anti-infective therapeutics - ProMore
Alternative Names: PXL 150; PXL-181Latest Information Update: 19 Apr 2023
Price :
$50
*
At a glance
- Originator Pergamum
- Developer ProMore Pharma
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Skin and soft tissue infections
Most Recent Events
- 19 Apr 2023 Discontinued - Preclinical for Skin and soft tissue infections in Sweden (Topical)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in Sweden (Topical)
- 30 Sep 2016 Promore Pharma announces intention to submit IND (Promore Pharma pipeline, September 2016)